In this three-center open-label study from November @ to May @ , we randomly assigned @ patients with advanced Child-Pugh class B or C HCC patients into two groups , one group with @ patient to receive sorafenib ( @ mg a time , twice a day ) and the other group with @ patients to receive best supportive care .